Study shows that regular acetaminophen use may be associated with an increased risk of psoriasis and psoriatic arthritis (PsA), and that long-term NSAID use may be associated with an increased risk of PsA.
Study results show patients with psoriatic arthritis, rheumatoid arthritis, and psoriasis are at higher risk for myocardial infarction, stroke, and other adverse cardiovascular events.
Cosentyx (secukinumab) has been approved in Japan for the treatment of psoriasis vulgaris (also known as plaque psoriasis) and psoriatic arthritis.
Psoriasis is associated with a higher risk of developing chronic kidney disease and glomerulonephritis, according to a study published online Dec. 15 in the British Journal of Dermatology.
A Phase 3 trial of the monoclonal antibody secukinumab indicates it is an effective treatment for patients with ankylosing spondylitis (AS) incompletely treated by standard therapy, according to data presented at the 2014 American College of Rheumatology meeting.
Rheumatic conditions may have an increased association with adverse cardiovascular events, according to research published in the Annals of Rheumatic Diseases.